Source-backedDelivery

Netherlands Psychedelic Therapy Workforce

A Dutch workforce-readiness page and scenario model for turning BIG-registered professionals into practical psychedelic-therapy capacity.

GZ psychologists: 21,524
Psychotherapists: 5,928
Psychiatrists: 4,163

At a glance

What to take from this page

The Netherlands has a large professional base, but headcount is not the same as launch capacity.
A realistic model must subtract overlap, part-time work, training access, credentialing, site attachment, sickness, ordinary caseload pressure, rooms, and medical cover.
Patient-population stock must be translated into annual addressable demand before comparing it with treatment capacity.

Who this helps

Clinicians and researchers

Place training initiatives in the wider professional-governance context.

Operators

Estimate where staffing and certification bottlenecks may appear.

Policy readers

Separate existing professional regulation from psychedelic-specific standards.

Step 1

Evidence

Step 2

Approval

Step 3

Reimbursement

Step 4

Delivery

Step 5

Access

Workforce and demand model

Convert Dutch professional registrations into treatment capacity

Registration counts are the outer base. The model then subtracts working share, relevance to adult GGZ, training access, credentialing, site attachment, ordinary caseload pressure, leave, diversion, rooms, and medical cover.

GZ psychologists

21,524

Outer BIG-register base; clinical psychologists sit inside this count.

Psychotherapists

5,928

Added with a unique-share correction to reduce double counting.

Psychiatrists

4,163

Mostly medical governance; only a share is counted as therapy delivery.

VS GGZ

1,975

Support-clinician reservoir, not a simple substitute for physician governance.

Interested in regulated PAT8%

Training access65%

Training completion90%

Credentialed in governed sites75%

Actually practicing75%

Private / underground diversion10%

Protected PAT time25%

Lead-hours per episode31h

Dosing sessions per therapist / week0.5

National dosing rooms25

TRD share of MDD stock25%

Annual referral / acceptance25%

Scenario assumptions

Read these as planning ranges, not forecasts

Interested professional share

Wide range

3-15% scenario range

Applied after working-share and relevance filters; reflects uncertainty about willingness to do intense, long-session PAT work.

Training-to-practice conversion

Scenario

Multi-step funnel

Training access, completion, credentialing, site employment, actual practice, diversion, and sickness are kept separate so training is not treated as legal or practical capacity.

Protected PAT availability

Wide range

5-50% of working time

Dosing sessions compete with ordinary GGZ caseloads. NZa reports a large existing mental-health care load, so redirecting staff has an opportunity cost.

Sourceable Dutch professional base used in the model

Role	Current sourceable base	How the model uses it
GZ psychologists	21,524 total; clinical psychologists sit inside this register	Main outer psychological lead-therapist reservoir, reduced by working and adult-GGZ relevance assumptions
Psychotherapists	5,928	Added with a unique-share correction because registrations can overlap with other specialisms
Psychiatrists	4,163	Main medical-governance pool; only a share is counted as possible therapy-delivery staff
Verpleegkundig specialist GGZ	1,975	Support-clinician and monitoring reservoir, not a simple substitute for psychiatrist governance
Nurses and pharmacists	Large outer registers	Site-level support and pharmacy governance only; not multiplied into therapist capacity

Registration counts are not availability. They include part-time work, non-adult settings, management, research, leave, and professionals who may not want psychedelic therapy work.

Workforce roles beyond the therapist pair

Role	Why it matters	Capacity risk
Psychiatrist / physician lead	Eligibility, prescribing or medical governance, adverse-event escalation	Limited specialist time and site governance obligations
Therapists / psychologists	Preparation, dosing support, integration, alliance, fidelity	Interest, training, supervision, and long-session scheduling
Nurses / medical monitors	Vitals, safety monitoring, coordination during dosing day	May be shared with other services and not psychedelic-specific
Pharmacy / medicine handling	Storage, dispensing, controlled-process documentation	Site-level readiness and standard operating procedures
Operations / data	Rooms, scheduling, registry, outcomes, consent, payer evidence	Administrative burden can be heavier for small practices

The Netherlands has signals, not a finished credential

Dutch readiness is best described as a set of partially aligned layers: regulated healthcare professions, psychiatry leadership, training infrastructure, ketamine/esketamine experience, and psychedelic-specific professional discussion.

BIG registration is not a psychedelic-therapy license. It is the outer professional-registration base; psychedelic therapy still needs indication-specific training, governance, supervision, site rules, payment, and room capacity.

The relevant number is available sessions, not registered professionals

The BIG-register gives a large outer professional base, but only a fraction would plausibly want to do psychedelic-assisted therapy, complete training, work in a certified setting, and reserve enough time for dosing days.

A practical launch model should therefore convert professionals into sessions cautiously: working share, overlap correction, interest, training access, training completion, credentialing, legal or reimbursed site access, actual practice, sickness and leave, protected PAT time, and private or underground diversion can all reduce available capacity.

Therapists: psychologists, psychotherapists, psychiatrists, and trained support roles where allowed.
Medical cover: psychiatrist or physician leadership, nurses, emergency protocols, and pharmacy handling.
Operations: rooms, scheduling, preparation, integration, data capture, supervision, and quality assurance.

Condition prevalence is not annual demand

The model separates people with a condition, clinically eligible people after treatment-history and contraindication gates, annual referral or acceptance, and treatment episodes per year.

This matters for TRD, MDD, and PTSD because a prevalence stock can look enormous, while a first-year reimbursed pathway may only treat a narrow and governed subset. The capacity gap is still likely to be large if protected therapist time and dosing rooms remain scarce.